We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Rheumatology

Journal Scan / Research · May 19, 2021

Association of Anti–Ro52 Positivity With Pulmonary Hypertension and Mortality in Systemic Sclerosis Patients

Scandinavian Journal of Rheumatology


Additional Info

Scandinavian Journal of Rheumatology
Anti-Ro52/TRIM21 Is Independently Associated With Pulmonary Arterial Hypertension and Mortality in a Cohort of Systemic Sclerosis Patients
Scand J Rheumatol 2021 Apr 14;[EPub Ahead of Print], A Lee, KA Patterson, DJ Tan, ME Wilson, SM Proudman, W Stevens, M Nikpour, J Sahhar, GS Ngian, J Roddy, PJ Roberts-Thomson, JG Walker

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading